Female Fertility and Pregnancy Rapid Test Market Overview
The global female fertility and pregnancy rapid test market size is projected to reach $489.3 million by 2022, growing at a CAGR of 4.5% during the forecast period. The market is driven by increasing prevalent cases with uterine malformations, increase in female geriatric population and increase in prevalent cases with PCOS. In addition, increasing infertility cases due to changes in lifestyle and growing demand of easy to use at home diagnostic devices are also driving the market.
Based on type of test, the female fertility and pregnancy rapid test market is segmented into FSH, LH and HCG test. The LH segment dominated the global market, and it is expected to retain its dominance by 2022, with 42.0% share. The segment is also expected to witness the fastest growth during the forecast period.
On the basis of product, the female fertility and pregnancy rapid test market is segmented into strips/dipsticks, cassettes/cards, and midstream. The strips/dipsticks segment dominated the global market, and it is expected to retain its dominance by 2022, with 50.2% share. The midstream segment is expected to witness the fastest growth during the forecast period.
Geographically, North America dominated the female fertility and pregnancy rapid test market, due to the increasing prevalence of uterine problems because of hormonal imbalance, such as irregular and heavy bleeding, unexplained miscarriages, and structural abnormalities of uterus, sub mucosal myomas and polyps leading to infertility. The growth of female aging population in the region also contributes to the growth of the North American female fertility and pregnancy rapid test industry, as aging leads to hormonal changes in females, thus making them more prone to PCOS, irregular menses and uterine malformations, which generates the need for hormone testing.
Female Fertility and Pregnancy Rapid Test Market Dynamics
The advantageous features possessed by the home diagnostic devices at home pregnancy and fertility rapid test attract the patients around the world to opt for such easy to use devices, instead of going for a lab-based test. At home, fertility and pregnancy rapid test are time saving, comparatively economical, helps to maintain privacy and can be used by the females at the comfort of their home. Thus, generating a high demand for at home diagnostic devices, which is leading to the growth of the female fertility and pregnancy rapid test market.
Also, the healthcare expenditure is increasing worldwide, due to the increasing prevalence of diseases and innovation of new medical treatments. According to the WHO, the total healthcare expenditure is increasing globally. The increase in healthcare expenditure leads to increased affordability and accessibility of the treatment for various conditions. This growth in healthcare expenditure supports the growth of the female fertility and pregnancy rapid test market.
The availability of alternative diagnostic test, such as blood test and reagent-based laboratory test are inhibiting the growth of the female fertility and pregnancy rapid test market. Laboratory based test are performed by skilled people with less chances of error. In addition, laboratory-based test provides correct result interpretation, which leads to their increased adoption in countries where people lack awareness about strips/dipsticks, cassettes/cards and midstream for diagnosis of FSH, LH and HCG in urine, thus hampering the growth of the market.
Also, the high cost of midstream acts as a major barrier in the growth of the female fertility and pregnancy rapid test market. The high cost of midstream, in comparison to strips/dipsticks and cassettes/cards make them less affordable by the patient pool. The patients suffer from fertility problems check their FSH, LH or HCG levels using strips/dipsticks or cassettes/cards as first line of diagnosis, as they are cheaper in comparison to midstream which makes midstream not affordable by everyone in developing countries, thus affecting the growth of the market.
Female Fertility and Pregnancy Rapid Test Market Competitive Landscape
The key companies operating in the female fertility and pregnancy rapid test market include Atlas Medical, Alere Inc., BioMerieux SA, Diagnostic Automation/Cortez Diagnostics Inc., Church & Dwight Co. Inc., SA Scientific, Gemc Technology Group Co. Ltd. and Nantong Egens Biotechnology Co. Ltd.